Topics

UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.

08:00 EDT 14th August 2019 | BioPortfolio

Summary of "UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY."

Regional nodal metastases carry prognostic significance in papillary thyroid cancer (PTC). However, whether different locational nodal metastases correlate with different therapeutic responses remains controversial. We innovatively applied the response to therapy re-stratification system (RTRS) to evaluate the dynamic disease status after surgery and radioiodine (RAI) therapy in PTC patients with different locational nodal metastases. A total of 585 non-distant-metastatic PTC patients who underwent total thyroidectomy and RAI therapy were retrospectively enrolled. Patients with nodal metastases were categorized into N1a and N1b groups. Propensity score matching (PSM) was used to balance the bias between two groups. Therapeutic responses were dynamically evaluated, and responses to RAI therapy were classified into excellent(ER), indeterminate(IDR), biochemical incomplete(BIR) and structural incomplete response(SIR). N1b group patients showed a significantly higher pre-ablation stimulated thyroglobulin (Ps-Tg) level than N1a group patients (7.4ng/mL vs 3.2ng/mL, <0.001). After RAI therapy, N1b group patients took longer time to achieve ER (9.86 months vs 3.29 months, <0.001) and exhibited a higher proportion of non-ER (IDR, BIR and SIR) (39.15% vs 17.46%, <0.001) compared to N1a group patients. In logistic regression, N1b and Ps-Tg≥10ng/mL were confirmed to be independent factors predicting non-ER (Odds Ratio, 2.591, 9.196, respectively). In Cox regression, patients with N1b disease and Ps-Tg≥10ng/mL showed significantly lower hazards for achieving ER (Hazard Ratio, 0.564, 0.223, respectively). N1b PTC patients showed inferior responses to surgery and RAI therapy compared to N1a patients. N1b was confirmed to be an independent factor predicting unfavorable responses to RAI therapy.

Affiliation

Journal Details

This article was published in the following journal.

Name: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
ISSN: 1530-891X
Pages:

Links

DeepDyve research library

PubMed Articles [26620 Associated PubMed Articles listed on BioPortfolio]

Physiologic Uterine Uptake of Radioiodine During Menstruation Demonstrated by SPECT/CT.

A 35-year-old woman with papillary thyroid cancer underwent I therapy after thyroidectomy. Post-therapy whole body scan revealed increased activity in the pelvis, in addition to the activity in the ne...

LncRNA MCM3AP-AS1 promotes proliferation and invasion through regulating miR-211-5p/SPARC axis in papillary thyroid cancer.

Long non-coding RNAs (lncRNAs) are an emerging class of regulators in cancer. A lncRNA, MCM3AP-AS1, has been demonstrated as a versatile mediator in many cancers, except papillary thyroid cancer. The ...

PROFILE AND CLINICAL OUTCOMES IN DIFFERENTIATED THYROID CANCER PATIENTS PRESENTING WITH BONE METASTASIS.

Differentiated thyroid cancer patients uncommonly present with bone metastasis as initial manifestation. Their molecular profile is largely unknown. The aim of this study was to evaluate histopatholog...

In-Depth Proteomics Analysis to Identify Biomarkers of Papillary Thyroid Cancer Patients Older Than 45 Years with Different Degrees of Lymph Node Metastases.

Investigations of the molecular mechanisms underlying the metastatic phenotype of papillary thyroid cancer and identification of novel candidate biomarkers to better predict papillary thyroid cancer m...

Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.

In DTC patients, 131-radioiodine therapy has routinely been used for many years for thyroid remnant ablation after thyroid surgery. To date, two different strategies can be used to achieve sufficient ...

Clinical Trials [16945 Associated Clinical Trials listed on BioPortfolio]

BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer

Papillary thyroid cancer (PTC) is the most common neoplasia in the thyroid gland. The combination of surgery, followed by radioiodine therapy (RIT) and thyroid-stimulating hormone (TSH) su...

Active Surveillance of Papillary Thyroid Microcarcinoma

Papillary thyroid microcarcinoma are small thyroid cancer measuring 1cm or less. Most of this tumor are not palpable and are identified either through pathologic examination or from imagin...

Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma

The purpose of this study is to assess whether therapy with Sorafenib reinduces radioiodine uptake in thyroid carcinoma.

Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences

To explore how a clinical sample of patients with thyroid nodules (men and women) with no history of thyroid cancer would make decisions about treatments based on different terminology use...

Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment

The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine ther...

Medical and Biotech [MESH] Definitions

A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)

An aggressive THYROID GLAND malignancy which generally occurs in IODINE-deficient areas in people with previous thyroid pathology such as GOITER. It is associated with CELL DEDIFFERENTIATION of THYROID CARCINOMA (e.g., FOLLICULAR THYROID CARCINOMA; PAPILLARY THYROID CANCER). Typical initial presentation is a rapidly growing neck mass which upon metastasis is associated with DYSPHAGIA; NECK PAIN; bone pain; DYSPNEA; and NEUROLOGIC DEFICITS.

Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.

Tumors or cancer of the THYROID GLAND.

Inflammatory disease of the THYROID GLAND due to autoimmune responses leading to lymphocytic infiltration of the gland. It is characterized by the presence of circulating thyroid antigen-specific T-CELLS and thyroid AUTOANTIBODIES. The clinical signs can range from HYPOTHYROIDISM to THYROTOXICOSIS depending on the type of autoimmune thyroiditis.

Quick Search


DeepDyve research library

Relevant Topics

Thyroid Disorders
The thyroid is a butterfly-shaped gland in the neck, just above thecollarbone and is an endocrine gland that make hormones. These Thyroid hormones control the rate of many activities in the body, including how fast the body burns calories and how fast th...

Surgical treatments
Surgery is a technology consisting of a physical intervention on tissues. All forms of surgery are considered invasive procedures; so-called "noninvasive surgery" usually refers to an excision that does not penetrate the structure being exci...


Searches Linking to this Article